Home - REPRIEVE Trial (original) (raw)

REPRIEVE Trial Results Have Been Incorporated Into Clinical Guidelines!

The primary results of the REPRIEVE Trial are now available online and show that pitavastatin calcium lowers the incidence rate of heart disease events by 36% in people with HIV. In February 2024, the Department of Health and Human Services Guidelines Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV released recommendations for the use of statin therapy in people with HIV.

Click here

to learn more about REPRIEVE, read the updated guidelines, and help us spread the word about these exciting results!

REPRIEVE Facts

REPRIEVE evaluated if a statin medication (pitavastatin calcium) is effective to prevent heart disease among people with HIV.

REPRIEVE is the largest randomized trial to date in HIV and results from REPRIEVE are helping clinical researchers and clinical care providers to develop heart disease prevention and treatment guidelines, specifically for people with HIV.

Number of Participants

7769

Mean Years Living with HIV

Manuscripts Published

Over 7500 Participants Have Joined REPRIEVE!

Here are two of their stories.

Marcus Conway,

College Park, Maryland, USA

"The best thing about participating in a clinical trial is learning more about a disease or illness. I believe that my participation in REPRIEVE has helped me to become more knowledgeable about HIV and heart disease prevention. I am hopeful that the results of REPRIEVE show that heart disease events can be prevented with the use of a statin medication."

Ernane Pinho,

Pavuna, Rio de Janeiro

“For me, REPRIEVE is important to monitor and control my cholesterol rates, and for the community living with HIV it is another form of care and prevention for good health.”